MedTrace Logo

The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID

NCT02971488 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 529

Last updated 2019-09-13

Study results available
· View outcomes & findings →

Summary

Screening, diagnosis and treatment of HCV in PWID, should be part of a harm reduction strategy. Treatment of HCV infected PWID should be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population. More frequent diagnosis, new methods that prevent loss of tracking, and access to antiviral treatment are all strategies that must be implemented jointly if the prevalence of HCV infection in our setting is to be reduced.

Conditions

  • Hepatitis C
  • Drug Users
  • Harm Reduction
  • HIV

Interventions

OTHER

Screening for HCV in PWID and Linkage-To-Care

Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy. Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population.

Sponsors & Collaborators

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Fundacion SEIMC-GESIDA

    collaborator OTHER

  • Hospital Universitario Infanta Leonor

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-15
Primary Completion
2018-12-31
Completion
2019-05-10

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02971488 on ClinicalTrials.gov